Santen Pharmaceutical Statistics

Total Valuation

Santen Pharmaceutical has a market cap or net worth of JPY 529.17 billion. The enterprise value is 444.01 billion.

Market Cap	529.17B
Enterprise Value	444.01B

Important Dates

The next estimated earnings date is Thursday, February 6, 2025.

Earnings Date	Feb 6, 2025
Ex-Dividend Date	Mar 28, 2025

Share Statistics

Santen Pharmaceutical has 342.62 million shares outstanding. The number of shares has decreased by -5.60% in one year.

Current Share Class	n/a
Shares Outstanding	342.62M
Shares Change (YoY)	-5.60%
Shares Change (QoQ)	-2.50%
Owned by Insiders (%)	0.11%
Owned by Institutions (%)	59.73%
Float	336.02M

Valuation Ratios

The trailing PE ratio is 21.15 and the forward PE ratio is 14.88. Santen Pharmaceutical's PEG ratio is 2.47.

PE Ratio	21.15
Forward PE	14.88
PS Ratio	1.82
PB Ratio	1.87
P/TBV Ratio	2.53
P/FCF Ratio	8.03
P/OCF Ratio	n/a
PEG Ratio	2.47

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.02, with an EV/FCF ratio of 6.74.

EV / Earnings	17.00
EV / Sales	1.47
EV / EBITDA	7.02
EV / EBIT	9.88
EV / FCF	6.74

Financial Position

The company has a current ratio of 2.61

Current Ratio	2.61
Quick Ratio	1.85
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	31.93

Financial Efficiency

Return on equity (ROE) is 8.79% and return on invested capital (ROIC) is 10.71%.

Return on Equity (ROE)	8.79%
Return on Assets (ROA)	7.62%
Return on Capital (ROIC)	10.71%
Revenue Per Employee	80.81M
Profits Per Employee	6.98M
Employee Count	3,744
Asset Turnover	0.72
Inventory Turnover	2.58

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +11.96% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+11.96%
50-Day Moving Average	1,724.31
200-Day Moving Average	1,666.24
Relative Strength Index (RSI)	25.53
Average Volume (20 Days)	1,505,005

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Santen Pharmaceutical had revenue of JPY 302.56 billion and earned 26.12 billion in profits. Earnings per share was 73.03.

Revenue	302.56B
Gross Profit	175.26B
Operating Income	50.96B
Pretax Income	29.64B
Net Income	26.12B
EBITDA	69.25B
EBIT	50.96B
Earnings Per Share (EPS)	73.03

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	84.44B
Total Debt	n/a
Net Cash	84.44B
Net Cash Per Share	246.46
Equity (Book Value)	288.25B
Book Value Per Share	827.65
Working Capital	134.61B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 73.23 billion and capital expenditures -7.35 billion, giving a free cash flow of 65.87 billion.

Operating Cash Flow	73.23B
Capital Expenditures	-7.35B
Free Cash Flow	65.87B
FCF Per Share	192.26

Full Cash Flow Statement

Margins

Gross margin is 57.92%, with operating and profit margins of 16.84% and 8.64%.

Gross Margin	57.92%
Operating Margin	16.84%
Pretax Margin	9.80%
Profit Margin	8.64%
EBITDA Margin	22.89%
EBIT Margin	16.84%
FCF Margin	21.77%

Dividends & Yields

This stock pays an annual dividend of 34.00, which amounts to a dividend yield of 2.20%.

Dividend Per Share	34.00
Dividend Yield	2.20%
Dividend Growth (YoY)	6.25%
Years of Dividend Growth	n/a
Payout Ratio	46.08%
Buyback Yield	5.60%
Shareholder Yield	7.80%
Earnings Yield	4.73%
FCF Yield	12.45%

Dividend Details

Stock Splits

The last stock split was on March 27, 2015. It was a forward split with a ratio of 5.

Last Split Date	Mar 27, 2015
Split Type	Forward
Split Ratio	5

Scores

Santen Pharmaceutical has an Altman Z-Score of 5.17.

Altman Z-Score	5.17
Piotroski F-Score	n/a